$SNEX

Maurer Mark Lowry sold $3.5M of SNEX

Maurer Mark Lowry sold 52,648 shares of StoneX Group Inc. (SNEX) at $66.25 ($3.49M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maurer Mark Lowry
Published Aug 11, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
medium confidence
Mentioned
$SNEX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

An open-market sale by an insider under a pre-arranged 10b5-1 plan is typically not a standalone fundamental driver, but it can slightly influence sentiment and short-term positioning.

02

Market read

Traders may treat this as a low-signal sentiment datapoint rather than a catalyst.

03

What to watch

The article does not state whether the sale was part of a larger series, nor does it provide context on total insider holdings beyond the post-transaction figure.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for StoneX Group Inc. (SNEX).

Company-level read

Ticker impact

$SNEXNeutralMedium confidence
Context

StoneX Group insider Maurer Mark Lowry filed a Form 4 open-market sale of 52,648 shares at $66.2501 on 2026-08-07.

Expected impact

Likely limited near-term impact; any effect would be small and short-lived unless paired with other company-specific news.

Evidence & confidence

The filing is a disclosed transaction size of about $3.49M, but the presence of a 10b5-1 plan reduces the likelihood of new, time-sensitive information.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with private concerns, so traders may still watch for follow-on disclosures or changes in insider behavior.

Key entities

  • StoneX Group Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Maurer Mark Lowry

    Reporter of the Form 4 open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.